News & Analysis on Clinical Trial Services & Contract Research And Development
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug development projects meet tight timelines and budget objectives.
In our latest whitepaper, discover how the power of high-quality PBPK modeling will better prepare you for those crucial preclinical and clinical phases.
With estimated savings of up to $2 million, you'll improve productivity and be first to market with life-changing treatments.
Paid for and in partnership with Lonza Small Molecules
Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How can they accelerate timelines and reduce costs?
Paid for and in partnership with Lonza Small Molecules
Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug synthesis, speeding up drug substance IND.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can be fraught with risk.
For more product information visit Lonza Small Molecules.